GlassScriptPhysician profile
Roxanne Altemus
NPI 1851527949
$7,866.25
in general payments reported to CMS, 2019-2025
17 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,244 · 2022: $1,120 · 2023: $1,764 · 2024: $1,663 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,453 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,453.28 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,513.94 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $929.53 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $790.43 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $693.60 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $399.36 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $387.48 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $293.07 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $216.08 | 2022-2025 | Rexulti |
| Boston Scientific Corporation | $117.15 | 2022 | |
| Impel Pharmaceuticals INC. | $113.40 | 2023 | Trudhesa |
| Corium, LLC | $109.55 | 2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $91.28 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $81.46 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.87 | 2025 | Cobenfy |
| Eisai INC. | $34.24 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2021 | |
| Owp Pharmaceuticals, INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxanne Altemus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.